Limits...
Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis.

Ford JA, Shyangdan D, Uthman OA, Lois N, Waugh N - BMJ Open (2014)

Bottom Line: We found no evidence of differences between ranibizumab, aflibercept, bevacizumab and triamcinolone for improving vision.The antivascular endothelial growth factors (VEGFs) are likely to be favoured because they are not associated with steroid-induced cataract formation.Not registered.

View Article: PubMed Central - PubMed

Affiliation: Department of Population Health and Primary Care, University of East Anglia, Norwich, UK.

No MeSH data available.


Related in: MedlinePlus

Network of randomised controlled trials comparing different treatments for proportions of gaining three or more lines of vision.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4120318&req=5

BMJOPEN2014005292F2: Network of randomised controlled trials comparing different treatments for proportions of gaining three or more lines of vision.

Mentions: The sufficiently comparable studies were combined into a network analysis based on a common comparator. The network for the proportions of patients gaining ≥3 lines is shown in figure 2. This network is the same for the other two outcomes, but without dexamethasone, because the trial did not report these outcomes.


Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis.

Ford JA, Shyangdan D, Uthman OA, Lois N, Waugh N - BMJ Open (2014)

Network of randomised controlled trials comparing different treatments for proportions of gaining three or more lines of vision.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4120318&req=5

BMJOPEN2014005292F2: Network of randomised controlled trials comparing different treatments for proportions of gaining three or more lines of vision.
Mentions: The sufficiently comparable studies were combined into a network analysis based on a common comparator. The network for the proportions of patients gaining ≥3 lines is shown in figure 2. This network is the same for the other two outcomes, but without dexamethasone, because the trial did not report these outcomes.

Bottom Line: We found no evidence of differences between ranibizumab, aflibercept, bevacizumab and triamcinolone for improving vision.The antivascular endothelial growth factors (VEGFs) are likely to be favoured because they are not associated with steroid-induced cataract formation.Not registered.

View Article: PubMed Central - PubMed

Affiliation: Department of Population Health and Primary Care, University of East Anglia, Norwich, UK.

No MeSH data available.


Related in: MedlinePlus